Letter: The Internet of Medical Things (IoMT): A New Frontier in the Digital Age for Rare Disease Clinical Trials and Global Drug Development

Abstract

Get full access to this article

View all access options for this article.

References

Abozaid

, Kerr

, Alomary

, et al. Global insight into rare disease and orphan drug definitions: A systematic literature review. BMJ Open, 2025; 15(1):e086527; doi: 10.1136/bmjopen-2024-086527

Gabbal

. Kevin Ashton describes “the internet of things.” The innovator weighs in on what human life will be like a century from now. Smithsonian Magazine. 2015 January issue. Available from: www.smithsonianmag.com/innovation/kevin-ashtondescribes-the-internet-of-things-180953749 [Last accessed: October 22, 2025].

Ghadessi

, Di

, Wang

, et al. Decentralized clinical trials and rare diseases: A Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective. Orphanet J Rare Dis, 2023; 18(1):79; doi: 10.1186/s13023-023-02693-7

Loru

, Nudo

, Di Marco

, et al. The simulation of judgment in LLMs. Proc Natl Acad Sci U S A, 2025; 122(42):e2518443122; doi: 10.1073/pnas.2518443122

Sato

, Ishimaru

, Takata

, et al. Application of internet of medical/health things to decentralized clinical trials: Development status and regulatory considerations. Front Med (Lausanne), 2022; 9:903188; doi: 10.3389/fmed.2022.903188